Platinum chemotherapy and hearing in cancer patients from deprived communities

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines hearing changes in cancer patients treated with platinum-based chemotherapy, focusing on how deprivation status may relate to risk. It will collect hearing and cognitive test results, along with demographic and health information, to understand patterns of hearing loss. The goal is to inform future care by identifying whether disadvantaged groups experience greater burden and whether screening or support needs differ by socioeconomic status.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients receiving platinum-based chemotherapy drugs
* Living and treated within North West England
* Able to complete an online hearing and cognitive test
* Fluent in English

Exclusion Criteria:

* Following cancer types: brain tumour/metastasis, head + neck, skin cancers around the ear, and adenoid cystic carcinoma of the auditory cortex
* World Health Organisation performance status score of 3 or more
* Stage 4 cancer
* History of childhood deafness
* Current or recent ear infections
* Cochlear implant user
* Known neurological impairment (e.g., stroke, traumatic brain injury, dementia)
* Patients who look capacity to consent or complete study tasks

Where it's running

• Lancaster University
  Lancaster, Lancashire, United Kingdom Recruiting

Study contacts

• Study coordinator: Helen Nuttall
• Email: h.nuttall1@lancaster.ac.uk
• Phone: 01524 592842

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gait Changes in Breast Cancer Patients Receiving Chemotherapy

  This study tests how chemotherapy affects walking and balance in women with breast cancer.

  Recruiting Cairo University · Cairo, Cairo Governorate · NCT07894133

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• VR-guided mindfulness for anxiety, sleep, comfort, and fatigue in women with breast cancer undergoing chemotherapy

  This study tests whether a virtual reality–based mindfulness program can help women with breast cancer feel less anxious, sleep better, feel more comfortable, and have less fatigue during chemotherapy.

  Recruiting Hacettepe University · Ankara, Ankara · NCT07731477

• Using plasma ctDNA methylation to guide adjuvant chemotherapy for high-risk T3N0 colorectal cancer

  This will test whether a blood ctDNA methylation test can help choose stronger chemotherapy after surgery for people with high-risk T3N0 (stage II) colorectal cancer who are ctDNA-positive one month after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562711

• Plasma ctDNA methylation-guided adjuvant chemotherapy for people with T4N0 and low‑risk stage III colorectal cancer.

  This trial will test whether using a blood test (plasma ctDNA methylation) to guide 3 vs 6 months of adjuvant chemotherapy or to switch regimens helps people with T4N0 or low‑risk stage III colorectal cancer after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562503

• Plasma ctDNA methylation–guided adjuvant chemotherapy for high-risk stage III colorectal cancer

  This trial will test whether adding bevacizumab to standard FOLFOX or CAPOX chemotherapy based on plasma ctDNA results helps adults with high-risk stage III colorectal cancer (T4N+ or T1-3N2).

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562490

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.